Department of Endocrinology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China.
Department of Traditional Chinese Medicine and Endocrinology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, PR China.
PLoS One. 2019 Jun 24;14(6):e0210930. doi: 10.1371/journal.pone.0210930. eCollection 2019.
In this study, we investigated the role and mechanism of Salt-induced kinase 1 (SIK1) in regulation of hepatic glucose and lipid metabolism in a high-fat food (HFD) and streptozocin (STZ)-induced type 2 diabetes mellitus (T2DM) rat model.
A diabetic rat model treated with HFD plus low-dose STZ was developed and was transduced to induce a high expression of SIK1 in vivo via a tail-vein injection of a recombinant adenoviral vector. The effects on hepatic glucogenetic and lipogenic gene expression, systemic metabolism and pathological changes were then determined.
In T2DM rats, SIK1 expression was reduced in the liver. Overexpression of SIK1 improved hyperglycaemia, hyperlipidaemia and fatty liver, reduced the expression of cAMP-response element binding protein (CREB)-regulated transcription co-activator 2 (CRTC2), phosphoenolpyruvate carboxykinase (PEPCK), glucose-6-phosphatase (G6Pase), pS577 SIK1, sterol regulatory element binding-protein-1c (SREBP-1c) and its target genes, including acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS), and increased the expression of SIK1, pT182 SIK1 and pS171 CRTC2 in diabetic rat livers with the suppression of gluconeogenesis and lipid deposition.
SIK1 plays a crucial role in the regulation of glucose and lipid metabolism in the livers of HFD/STZ-induced T2DM rats, where it suppresses hepatic gluconeogenesis and lipogenesis by regulating the SIK1/CRTC2 and SIK1/SREBP-1c signalling pathways. Strategies to activate SIK1 kinase in liver would likely have beneficial effects in patients with T2DM and nonalcoholic fatty liver disease (NAFLD).
本研究旨在探讨盐诱导激酶 1(SIK1)在高脂饮食(HFD)和链脲佐菌素(STZ)诱导的 2 型糖尿病(T2DM)大鼠模型中调节肝糖和脂代谢中的作用和机制。
通过尾静脉注射重组腺病毒载体,在糖尿病大鼠模型中诱导 SIK1 高表达,构建高表达 SIK1 的糖尿病大鼠模型,然后检测其对肝糖异生和脂生成基因表达、全身代谢和病理变化的影响。
在 T2DM 大鼠中,肝脏 SIK1 表达减少。过表达 SIK1 可改善高血糖、高脂血症和脂肪肝,降低 cAMP 反应元件结合蛋白(CREB)调节的转录共激活因子 2(CRTC2)、磷酸烯醇丙酮酸羧激酶(PEPCK)、葡萄糖-6-磷酸酶(G6Pase)、pS577 SIK1、固醇调节元件结合蛋白-1c(SREBP-1c)及其靶基因乙酰辅酶 A 羧化酶(ACC)和脂肪酸合酶(FAS)的表达,增加糖尿病大鼠肝脏中 SIK1、pT182 SIK1 和 pS171 CRTC2 的表达,抑制糖异生和脂质沉积。
SIK1 在 HFD/STZ 诱导的 T2DM 大鼠肝脏葡萄糖和脂质代谢调节中起关键作用,通过调节 SIK1/CRTC2 和 SIK1/SREBP-1c 信号通路,抑制肝糖异生和脂生成。激活肝脏 SIK1 激酶的策略可能对 T2DM 和非酒精性脂肪性肝病(NAFLD)患者有益。